Full-Time
Director of Procurement
Global Development & Medical Services
Updated on 7/22/2026
Biogen
5,001-10,000 employees
Develops therapies for neurological disorders
Compensation Overview
$184k - $253k/yr
Cambridge, MA, USA
Hybrid
Hybrid role; on-site days not specified.
 Business & Strategy (2) |
|---|
| , |
Get referred to Biogen
Find people who can refer or advise you
- Undergraduate degree or equivalent combination of education and experience required
- 12+ years of related leadership experience including 6+ years of clinical or adjacent category management, and at least 3 years in team management in a global environment
- Proven leadership of high impact teams and ability to mentor and coach team members to develop strategic capabilities
- Ability to influence, collaborate, and communicate effectively with strong stakeholder management skills, building trust across cross-functional teams and senior business partners
- Demonstrated ability to lead complex, global procurement initiatives and manage multiple high-priority projects simultaneously, ensuring alignment with strategic objectives, timelines, and stakeholder expectations
- Expertise in prioritizing, organizing, and multitasking in a dynamic environment
- Proven value generation from both internal and external opportunities
- Proficiency with digital procurement tools, advanced analytics, automation, and AI-enabled insights
- Proficiency in sophisticated negotiations across varied commercial models and deal structures, including CROs, Clinical Technologies, and Medical Affairs
- Lead a team of Global Category Managers to build and refresh strategic category strategies grounded in external market signals and internal demand, to enable business acceleration
- Drive Global Supplier Relationship Management for strategic partners, lead Business Operations Committee governance, Quality, Compliance, and supplier performance management to enable business goals and objectives
- Utilize spend data analytics, market intelligence, and benchmarking to identify value opportunities, optimize vendor services, drive cost reduction and avoidance improving value return in alignment with Finance
- Partner with senior stakeholders to build relationships and coordinate structured decision making across diverse teams that facilitate business alignment, acceleration, and value
- Set and execute negotiation strategies and playbooks for complex global master service agreements, rate cards, rebates, and commercial terms to secure value, control, and speed
- Ensure efficiency of procurement events through optimal use of buying channels, program implementations of tools and systems that drives successful execution while managing risks and clear stakeholder communication
- Evaluate vendor landscape to align preferred suppliers meeting the business’ priorities across Business Units, Therapeutic Areas, and Global environment to ensure consistency, compliance and outcomes
Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1978
Get referred to Biogen
Find people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approval of Leqembi IQLIK at-home autoinjector accelerates early Alzheimer's adoption and offsets MS revenue decline.
- Phase 3 advancement of diranersen offers first non-amyloid Alzheimer's mechanism with potential $3B+ 2030 revenue optionality.
- Apellis acquisition consolidates pegcetacoplan franchise targeting $785M by 2032, prioritizing high-margin immunology assets.
What critics are saying
- Italian AGCM forces Stratify test unbundling from Tysabri within 12–18 months, eroding 70% MS market share and triggering €100M+ fines.
- Sandoz Tyruko biosimilar price war collapses Tysabri's €1.2B Italian revenue within 6–12 months, compressing MS prices by 30–40%.
- Diranersen Phase 3 failure likely in 18–24 months due to missed primary CDR-SB endpoint, eliminating Alzheimer's optionality despite FDA flexibility.
What makes Biogen unique
- Biogen leads neuroscience with Leqembi, the only anti-amyloid Alzheimer's therapy with at-home autoinjector access.
- It pioneers anti-tau therapy diranersen, showing unprecedented 50–65% CSF tau reductions in Phase 2 trials.
- The company dominates multiple sclerosis with Tysabri, holding over 70% market share in key European markets.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -10%1 year growth
↓ -10%2 year growth
↓ -10%Italy: the AGCM opens a formal investigation into Biogen for alleged abuse of dominant position in the multiple sclerosis drug market. Published. Jul 14 2026 Practices. Sectors. Regions. Countries. Offices. I. Premise. On 19 May 2026, the Italian Competition and Market Authority (AGCM) opened a formal investigation against Biogen Italia S.r.l. and its ultimate parent company Biogen Inc. The company is active in the research, development and commercialisation of biopharmaceutical products, including the biological drug Tysabri (natalizumab), which is used in the treatment of multiple sclerosis. The investigation concerns an alleged abuse of dominant position in violation of Article 102 of the Treaty on the Functioning of the European Union (TFEU). II. The alleged conduct. Tysabri, Biogen's originator product, has been available on the Italian market since February 2007 and enjoyed patent protection until February 2024, following which Sandoz introduced its biosimilar Tyruko in April 2024, priced approximately 20% below the originator. Patients treated with natalizumab (NZB) must undergo periodic anti-JCV antibody testing to assess the risk of developing progressive multifocal leukoencephalopathy (PML), a potentially fatal condition. Biogen has developed one such test - Stratify - in collaboration with Quest Diagnostics, offered free of charge to patients treated with Tysabri through the Unilabs laboratory network, and protected by patent until 2032. The AGCM suspects that since at least 2019 Biogen has pursued an exclusionary strategy by tying the Stratify test exclusively to Tysabri, and simultaneously refusing to make it available to patients prescribed Sandoz's competing biosimilar Tyruko. Biogen is also alleged to have filed multiple divisional patents - most of which have since been invalidated - seeking to link Stratify to NZB-based treatment, and to have configured its digital platform to deny test access to patients not prescribed Tysabri. Despite repeated requests from Sandoz between 2023 and 2025, Biogen has not made the Stratify test available for use in conjunction with Tyruko. III. The relevant markets and dominant position. The AGCM has identified two distinct relevant markets, both national in geographic scope: the market for anti-JCV laboratory diagnostic screening services and the market for NZB-based multiple sclerosis treatments. Biogen holds a share exceeding 70% in both markets and is accordingly considered to hold a dominant position in each. The Stratify test has become the de facto clinical standard for PML risk stratification, underpinned by over 15 years of patient data. IV. Key takeaways. * This case demonstrates a significant development in Italian pharmaceutical antitrust enforcement by combining classic tying and refusal-to-deal theories in the context of biosimilars. * Companies dominant in a related ancillary market (e.g. a proprietary diagnostic tool) should carefully consider whether restricting access to that tool could have anti-competitive effects in a neighbouring product market. The AGCM decision (in English) is available at the following link.
Cancer vaccine shows promise in early trials. Medical research breakthrough: novel cancer vaccine advances to human trials. Washington D.C. - In a significant development for oncology, researchers announced today, July 8, 2026, that a groundbreaking cancer vaccine has demonstrated remarkable potential in early-stage preclinical trials. This innovative therapy, developed by a collaborative team from the National Institutes of Health (NIH) and biotech firm BioGen Innovations, targets specific mutations found in a range of aggressive cancers, offering a new avenue for treatment and potentially shifting the paradigm in cancer care. The experimental vaccine, codenamed BG-1926, utilizes messenger RNA (mRNA) technology, similar to that employed in some successful COVID-19 vaccines, to prime the patient's immune system to recognize and attack cancerous cells. Unlike traditional treatments that often cause widespread side effects, BG-1926 is designed to be highly specific, aiming to minimize harm to healthy tissues. Preclinical studies conducted over the past two years on animal models showed a significant reduction in tumor size and metastasis in subjects treated with the vaccine, with minimal observed toxicity. How BG-1926 works. The core of BG-1926's innovation lies in its ability to identify and target neoantigens - unique protein fragments that appear on the surface of cancer cells due to genetic mutations. By introducing these neoantigens via mRNA, the vaccine trains T-cells, a crucial component of the immune system, to identify these abnormal proteins as foreign invaders and mount a targeted attack. This personalized approach means that the vaccine can, in theory, be tailored to an individual's specific cancer mutations, maximizing its efficacy. Dr. Evelyn Reed, lead researcher at the NIH's National Cancer Institute, explained the significance of this approach. "For years, the challenge has been to harness the power of the immune system to fight cancer without causing overwhelming collateral damage," Dr. Reed stated in a press briefing. "BG-1926 represents a leap forward because it's designed for precision. We're essentially teaching the body's own defenses to do the heavy lifting, specifically targeting the enemy while leaving friendly forces - healthy cells - unharmed." Transition to human trials. Following the promising preclinical data, BioGen Innovations announced it has received regulatory approval to commence Phase 1 human trials. These initial trials will focus on safety and tolerability, involving a small cohort of patients with advanced-stage pancreatic and ovarian cancers, two types known for their aggressive nature and limited treatment options. The trials are set to begin in late July 2026 at leading cancer research centers across the United States. "This is a critical milestone," said Mark Johnson, CEO of BioGen Innovations. "The transition from laboratory success to human application is where the real work begins, but we are incredibly optimistic about the potential of BG-1926 to make a tangible difference in the lives of cancer patients. We are committed to a rigorous and transparent trial process." Challenges and future outlook. While the excitement surrounding BG-1926 is palpable, experts caution that the journey from Phase 1 trials to widespread clinical use is long and complex. Many promising therapies falter in later stages of testing. Key challenges include ensuring consistent manufacturing of the personalized vaccines, managing potential immune-related side effects, and demonstrating clear survival benefits over existing treatments. However, the underlying technology has been rapidly advancing. The success of mRNA vaccines in combating the global pandemic has accelerated research in applying this platform to other diseases, including cancer. If BG-1926 proves successful, it could pave the way for similar vaccines targeting other forms of cancer, potentially including lung, colon, and breast cancers. The medical community is watching closely. This potential medical research breakthrough underscores the ongoing commitment to innovation in fighting one of humanity's most persistent adversaries. Further updates on the BG-1926 trials are anticipated by the end of 2026.
Axtria Ignite 2026: 450+ life sciences leaders convene with a contrarian message - fix the foundation before you scale AI. Jun 26, 2026 * More than 450 executives from 100+ leading life sciences organizations gathered in Princeton, NJ to move agentic AI past the proof-of-concept stage * Founder and CEO Jaswinder "Jassi" Chadha challenged the industry with a counterintuitive mandate: before you build more agents, fix the foundation first * The Ignite Leadership Awards honored transformation leaders from Bristol Myers Squibb, GSK, and Biogen; the Axtria Bedrock Honor recognized a 15-year partnership with Quest Diagnostics BERKELEY HEIGHTS, N.J., June 25, 2026 /PRNewswire/ - Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme "Industrializing Intelligence: The Agentic Enterprise." More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed. Day 1 of the by-invitation-only event drew more than 200 attendees to product workshops on practical applications of AI, analytics, and commercial excellence. It included real-world success stories and value delivered from agents and hands-on experience with live agents. Day 2 featured four mainstage sessions and 16 panels across four tracks: industrialized data and the agentic backbone, agentic AI for business insights, high-performance customer engagement, and the shift from software to agentic ecosystems. Now in its fourth year, Axtria Ignite has become a regular fixture on the calendars of senior commercial and data leaders in life sciences. The foundation is the strategy In his keynote address, Axtria founder and CEO Jaswinder "Jassi" Chadha argued that the foundation determines whether AI in pharma scales. Drawing on three decades in the industry, he pointed to the persistent gap between ambition and execution: roughly 73% of biopharma still reports significant data issues, as many as 89% of AI pilots never reach production, and trust in AI systems has slipped from 61% in 2019 to 53% today, even as the industry races toward a projected 100,000-plus AI agents. Against a pharma accuracy bar of 99.5%, Chadha laid out four things the foundation must carry: an AI-ready data supply chain, a semantic layer for agent accuracy, software guardrails for deterministic precision where stakes are highest, and a governance framework for digital workers at scale. Agents, in his framing, are new hires who must earn trust through validation and audit, not receive it on day one. "Before you build the agent, fix the foundation first. The companies that will lead the agentic era are not the ones who moved fastest; they are the ones who built them with trust," Jaswinder "Jassi" Chadha, Founder and CEO, Axtria. Proving CFO-certifiable business value Co-founder and CTO Navdeep "Navi" Chadha led a mainstage session with senior leaders from Thermo Fisher Scientific and Quest Diagnostics. The discussion moved past future potential to candid accounts of what has worked and what has not, from CFO-certifiable value reporting and integrated risk management to the discipline of defining exit criteria before a proof of concept begins. A recurring lesson surfaced across panelists: change management is the work, not a footnote. "Change management and adoption cannot be the 45th slide in a 30-page deck at the business case approval," Senior Digital Leader, speaking on a mainstage panel. The conversations attendees took home Across tracks, the discussions reached a level of candor that does not show up in industry research reports. A senior leader at a major pharma company described her team's unlock: making clear that AI was here to elevate marketers rather than replace them. By her account, adoption now stands at over 90%. "This is not an AI revolution. It's a people revolution," VP of Commercial AI at a top pharma company, closing mainstage session. Ignite Leadership Awards Axtria presented its annual Ignite Leadership Awards, recognizing leaders doing the hard work of transformation inside their organizations. These leaders were recognized for driving enterprise-wide AI transformations and genuinely bringing multiple disciplines together to truly make a difference to the foundation of AI to realize the true value. The 2026 honorees were: * Anvita Karara, Vice President, Commercialization AI Strategy & Analytics, Bristol Myers Squibb * Jeremy Pincus, Vice President, Medical Affairs IT, GSK * Bharti Rai, Senior Vice President, Biogen Axtria Bedrock Honor The Axtria Bedrock Honor recognized Quest Diagnostics for a 15-year partnership and the recent implementation of an Axtria SalesIQ sales force alignment solution across 34 role types and a ~1,300-person field organization, among the most complex sales force alignments in healthcare. The honor was accepted by John Liffert, Vice President, Commercial Operations, alongside Samantha Barnes-Weaver, Director, National Deployment and Alignments, and Marc Cangemi, Senior Director, Commercial Excellence, Compensation, and Deployment. "Those of you who know the Quest business know it's probably the most complex sales force alignment in healthcare. Because we were able to solve that, you made us better. You made our product better. Thank you for being our partners in this journey," Jassi Chadha, Founder and CEO, Axtria. About the event Ignite 2026 featured 45+ speakers across panels and presentations, plus hands-on workshops with Axtria's agentic products, including Axtria HIQ, Axtria SalesIQ, Axtria MarketingIQ, and Axtria DataMAx. The agenda also included an Executive Incentive Compensation Roundtable and networking receptions on both evenings. About Axtria Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. A leading global provider of award-winning cloud software and data analytics, Axtria delivers proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action. As a participant in the United Nations Global Compact, Axtria is committed to aligning its strategies and operations with universal principles on human rights, labor, environment, and anti-corruption. For more information, visit www.axtria.com. Facebook Comment
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
Biogen has agreed to acquire RayThera, a private biotechnology company focused on small molecule immunology therapies, for up to $1 billion. The deal comprises an upfront payment and predominantly milestone-based payments tied to clinical and regulatory achievements. RayThera's portfolio includes multiple anti-inflammatory assets targeting immune-mediated conditions. The lead candidate is expected to enter Phase 1 development in early Q3 2026. RayThera recently completed its Series A financing co-led by Foresite Capital and OrbiMed Advisors. The transaction, subject to customary closing conditions and regulatory approvals, is anticipated to close in Q3 2026. Once completed, Biogen will lead development, manufacturing and global commercialisation of the acquired assets, expanding its immunology pipeline into new disease areas.